An interventional study of Uterosacral ligament suspension and Uphold® LITE in Uterovaginal Prolapse, sponsored by NICHD Pelvic Floor Disorders Network. Completed at 8 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by NICHD Pelvic Floor Disorders Network · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this randomized clinical trial is to compare the effectiveness and safety of two transvaginal apical suspension strategies for uterovaginal prolapse: a mesh augmented hysteropexy versus vaginal hysterectomy and uterosacral ligament suspension (USLS). The primary aim is to determine whether treatment success in women who undergo the above strategies differ at time points through 3 years.
A supplemental study investigates anterior vaginal wall movement resulting from descent or rotation of the vaginal apex and/or anterior vaginal elongation, in women in both of the study arms of SUPeR.
The study population will be adult women (>21 years of age) with symptomatic uterovaginal prolapse at or beyond the hymen who desire vaginal surgical management. This study is intended to be done only on women who have completed child-bearing and have an inactive uterus, defined as amenorrhea for 1 year. Therefore women will be postmenopausal or will have amenorrhea from an endometrial ablation. Amenorrhea caused from exogenous steroids, or hypothalamic disorders will not allow inclusion.
Participants will be obtained from the clinic population of each of the eight Pelvic Floor Disorders Network (PFDN) sites. Participants will be randomly assigned to have either vaginal hysterectomy and USLS or mesh hysteropexy suspension for treatment of their uterovaginal prolapse. The surgical assignment will be revealed in the operating room, after the participant is under anesthesia.
Participants will be followed for at least 36-months (3-years) post surgery and up to a maximum of 60-months (5-years) during the primary trial. Participants who complete the primary trial will be approached for consent for long-term follow-up as part of a study extension and will be followed up to a maximum of 120-months (10-years). Follow-up data will be obtained during in-person clinic visits, and study staff who are masked to the surgical assignment will be the primary person who obtain follow-up data. Although the primary study outcome does not depend on masked participants and blinded evaluators, several important participant reported secondary aims are subject to reporting bias if the participant is aware of her study assignment. Therefore, study participants, coordinators, and nurses will be masked to the study assignment. Study surgeons and anatomic evaluators will be unmasked. Evaluators conducting the POPQ exam will be a co-investigator, fellow or other qualified nurse who did not perform the study surgery.
Surgical failure rates will be compared using survival analysis approaches appropriate for interval censored data (classic log-rank tests and survival models using a generalized linear model approach with a complementary log-log link) and secondary outcomes will be reported as rates in each group or as group means and evaluated with the appropriate parametric or nonparametric statistical tests.
Throughout the study, the PFDN Data Safety and Monitoring Committee (DSMB) will review study data and decide if the study can or cannot continue. Additionally, this study will adhere to the CONSORT guidelines for performing and reporting randomized controlled trials (Begg et al 1996). Women who are eligible but decline enrollment will be characterized in a manner consistent with CONSORT requirements.
NICHD Pelvic Floor Disorders Network is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Uphold® LITE
Procedure: Uphold® LITE
Vaginal hysterectomy and uterosacral ligament suspension (USLS)
Procedure: Uterosacral ligament suspension
The USLS procedure used in this protocol is a modification of the technique described by Shull.
The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
Cumulative Failure
Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.
Time frame: 6 Months through 36 Months
At-visit Failure
Failure was defines as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the transient failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study. Similarly, the denominator number of participants for the transient failure at each visit includes all participants who were still participating in the study and attended the visit or who missed the visit but had a retreatment failure outcome prior to their missed visit.
Time frame: 6 months through 36 Months
Change From Baseline PFDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline CRADI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline POPDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline UDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline PFIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline CRAIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline POPIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline UIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Incontinence Severity Index
Incontinence Severity Index measuring the severity of urinary incontinence is composed of 2 questions: frequency of leakage (0=Never,...,4=Every day/night) and amount of urine leakage (1=Drops, 2=small splashes, 3= More). The index score is calculated categorizing the product of the two responses. The range of responses is: 0 (no incontinence) to 12 (severe incontinence). Lower index scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Functional Activity Scale
Functional Activity Scale measuring the impact of incontinence symptoms on a woman''s daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Body Part Pain Scale
The Body Part Pain Scale measuring the the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, 30, and 36 Months
Change From Baseline Surgical Pain Scale Rest Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Surgical Pain Scale Normal Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Surgical Pain Scale Exercise Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Surgical Pain Scale Worst Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline Body Image Scale
The Body Image Scale measuring how the subjects feel about their appearance and about any changes that may have resulted from their condition consists of 8 questions. The questions are scored from 0=Not at all,..., 3=Very much. The score is calculated by summing the responses and ranges from 0 to 24. Higher scores correspond to worse body image. Change = Month \[6, 12, 18, 24, and 36\] Score - Baseline Score.
Time frame: 6, 12, 18, 24, and 36 Months
Change From Baseline PISQ-IR Sexually Active Average Score
The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.
Time frame: 6, 12, 18, 24, and 36 Months
POP-Q Ba Measurement
The Pelvic Organ Prolapse Quantification (POPQ) Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.
Time frame: 12, 24, and 36 Months
POP-Q Bp Measurement
The Pelvic Organ Prolapse Quantification (POPQ) Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).
Time frame: 12, 24, and 36 Months
POP-Q C Measurement
The Pelvic Organ Prolapse Quantification (POPQ) Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.
Time frame: 12, 24, and 36 Months
POP-Q TVL Measurement
The Pelvic Organ Prolapse Quantification (POPQ) Total Vaginal Length (TVL) is the length of the vagina from posterior fornix tothe hymen when Point C or D is reduced to its full normal position.
Time frame: 12, 24, and 36 Months
PGI-I
The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).
Time frame: 6,12, 18, 24, and 36 Months
| Milestone | Hysteropexy | Hysterectomy and USLS |
|---|---|---|
| Started | 93 | 90 |
| Eligible and received randomized treatment | 88 | 87 |
| Completed year 1 follow-up | 88 | 86 |
| Completed year 2 follow-up | 87 | 84 |
| Completed | 85 | 84 |
| Not completed | 8 | 6 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Ineligible | 5 | 3 |
Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.
| Participants | UPHOLD | USLS |
|---|---|---|
| 6 Months — Non-Failure | 78 | 69 |
| 6 Months — Failure | 9 | 16 |
| 12 Months — Non-Failure | 71 | 63 |
| 12 Months — Failure | 15 | 22 |
| 18 Months — Non-Failure | 66 | 58 |
| 18 Months — Failure | 19 | 26 |
| 24 Months — Non-Failure | 59 | 54 |
| 24 Months — Failure | 21 | 29 |
| 30 Months — Non-Failure | 55 | 52 |
| 30 Months — Failure | 24 | 31 |
| 36 Months — Non-Failure | 53 | 47 |
| 36 Months — Failure | 26 | 34 |
Failure was defines as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the transient failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study. Similarly, the denominator number of participants for the transient failure at each visit includes all participants who were still participating in the study and attended the visit or who missed the visit but had a retreatment failure outcome prior to their missed visit.
| Participants | UPHOLD | USLS |
|---|---|---|
| 6 Months — Non-failure | 78 | 69 |
| 6 Months — Failure | 9 | 16 |
| 12 Months — Non-failure | 74 | 65 |
| 12 Months — Failure | 12 | 19 |
| 18 Months — Non-failure | 69 | 65 |
| 18 Months — Failure | 15 | 18 |
| 24 Months — Non-failure | 64 | 63 |
| 24 Months — Failure | 15 | 17 |
| 30 Months — Non-failure | 60 | 60 |
| 30 Months — Failure | 18 | 18 |
| 36 Months — Non-failure | 62 | 57 |
| 36 Months — Failure | 16 | 21 |
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -81.7 (-93.3 to -70.1) | -73 (-84.8 to -61.1) |
| 12 Months | -81.2 (-92.9 to -69.6) | -75.4 (-87.3 to -63.5) |
| 18 Months | -78.7 (-90.5 to -67) | -75.8 (-87.8 to -63.9) |
| 24 Months | -82.1 (-93.9 to -70.2) | -76.6 (-88.7 to -64.5) |
| 36 Months | -79.8 (-91.7 to -67.8) | -80.1 (-92.3 to -67.8) |
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -11.5 (-15.6 to -7.4) | -11.1 (-15.3 to -6.9) |
| 12 Months | -11.1 (-15.2 to -7) | -11.2 (-15.4 to -7) |
| 18 Months | -10.6 (-14.8 to -6.5) | -11.9 (-16.1 to -7.6) |
| 24 Months | -12.4 (-16.6 to -8.2) | -11.4 (-15.7 to -7.2) |
| 36 Months | -11.4 (-15.6 to -7.2) | -11.6 (-15.9 to -7.2) |
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -40.7 (-45.7 to -35.7) | -37 (-42.1 to -31.9) |
| 12 Months | -41.1 (-46 to -36.1) | -37.4 (-42.5 to -32.3) |
| 18 Months | -40.3 (-45.3 to -35.3) | -37.4 (-42.5 to -32.3) |
| 24 Months | -41.2 (-46.3 to -36.2) | -38 (-43.1 to -32.8) |
| 36 Months | -40.1 (-45.2 to -35) | -40.2 (-45.5 to -35) |
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -29.5 (-35.2 to -23.8) | -24.8 (-30.7 to -19) |
| 12 Months | -29.1 (-34.8 to -23.3) | -26.8 (-32.7 to -20.9) |
| 18 Months | -27.8 (-33.6 to -22) | -26.6 (-32.5 to -20.7) |
| 24 Months | -28.4 (-34.3 to -22.6) | -27.3 (-33.3 to -21.3) |
| 36 Months | -28.3 (-34.2 to -22.4) | -28.2 (-34.3 to -22.2) |
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -42.9 (-53.9 to -31.9) | -46.7 (-57.9 to -35.5) |
| 12 Months | -38.3 (-49.3 to -27.3) | -47.4 (-58.7 to -36.2) |
| 18 Months | -40.1 (-51.2 to -29.1) | -50.1 (-61.4 to -38.8) |
| 24 Months | -44 (-55.1 to -32.8) | -48.8 (-60.2 to -37.4) |
| 36 Months | -43.4 (-54.6 to -32.2) | -50.4 (-61.9 to -38.8) |
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -6.7 (-10.8 to -2.6) | -10.1 (-14.3 to -5.9) |
| 12 Months | -4.7 (-8.8 to -0.6) | -9.5 (-13.7 to -5.3) |
| 18 Months | -4.6 (-8.7 to -0.5) | -9.6 (-13.8 to -5.4) |
| 24 Months | -7.3 (-11.4 to -3.1) | -9.7 (-13.9 to -5.4) |
| 36 Months | -6.1 (-10.3 to -1.9) | -9.8 (-14.1 to -5.5) |
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -15.7 (-20.6 to -10.9) | -18.9 (-23.9 to -13.9) |
| 12 Months | -14.6 (-19.4 to -9.7) | -19.5 (-24.5 to -14.5) |
| 18 Months | -15.9 (-20.8 to -11.1) | -20.1 (-25.1 to -15.1) |
| 24 Months | -15.9 (-20.8 to -11) | -19.1 (-24.1 to -14) |
| 36 Months | -16 (-21 to -11.1) | -19.9 (-25 to -14.8) |
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -20.5 (-25.5 to -15.5) | -17.7 (-22.8 to -12.6) |
| 12 Months | -19 (-24 to -14.1) | -18.4 (-23.5 to -13.4) |
| 18 Months | -19.5 (-24.5 to -14.6) | -20.4 (-25.5 to -15.3) |
| 24 Months | -20.8 (-25.8 to -15.7) | -20.1 (-25.3 to -15) |
| 36 Months | -21.3 (-26.3 to -16.2) | -20.6 (-25.8 to -15.4) |
Incontinence Severity Index measuring the severity of urinary incontinence is composed of 2 questions: frequency of leakage (0=Never,...,4=Every day/night) and amount of urine leakage (1=Drops, 2=small splashes, 3= More). The index score is calculated categorizing the product of the two responses. The range of responses is: 0 (no incontinence) to 12 (severe incontinence). Lower index scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -2.4 (-3.2 to -1.6) | -1.3 (-2.1 to -0.6) |
| 12 Months | -2.1 (-2.9 to -1.3) | -1.4 (-2.2 to -0.6) |
| 18 Months | -2.1 (-2.9 to -1.3) | -1.3 (-2.1 to -0.5) |
| 24 Months | -1.9 (-2.7 to -1.2) | -1.4 (-2.2 to -0.6) |
| 36 Months | -1.9 (-2.7 to -1.1) | -1.6 (-2.5 to -0.8) |
Functional Activity Scale measuring the impact of incontinence symptoms on a woman''s daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | 6.3 (3.5 to 9) | 7.7 (4.9 to 10.5) |
| 12 Months | 6.3 (3.6 to 9.1) | 6 (3.2 to 8.8) |
| 18 Months | 5.8 (3 to 8.5) | 6.6 (3.8 to 9.5) |
| 24 Months | 4.9 (2.1 to 7.7) | 6.2 (3.3 to 9) |
| 36 Months | 5.6 (2.8 to 8.5) | 4.8 (1.9 to 7.7) |
The Body Part Pain Scale measuring the the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -0.4 (-0.6 to -0.2) | -0.3 (-0.5 to -0.1) |
| 12 Months | -0.5 (-0.7 to -0.3) | -0.3 (-0.5 to -0.1) |
| 18 Months | -0.5 (-0.7 to -0.3) | -0.3 (-0.5 to -0.1) |
| 24 Months | -0.6 (-0.8 to -0.3) | -0.3 (-0.6 to -0.1) |
| 30 Months | -0.5 (-0.7 to -0.3) | -0.3 (-0.5 to -0.1) |
| 36 Months | -0.5 (-0.7 to -0.3) | -0.3 (-0.5 to -0.1) |
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -0.7 (-1.1 to -0.3) | -0.8 (-1.2 to -0.3) |
| 12 Months | -0.6 (-1 to -0.2) | -0.7 (-1.1 to -0.2) |
| 18 Months | -0.6 (-1 to -0.2) | -0.8 (-1.2 to -0.4) |
| 24 Months | -0.7 (-1.2 to -0.3) | -0.5 (-0.9 to -0.1) |
| 36 Months | -0.5 (-1 to -0.1) | -0.6 (-1.1 to -0.2) |
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -0.9 (-1.3 to -0.4) | -0.8 (-1.3 to -0.4) |
| 12 Months | -0.9 (-1.3 to -0.4) | -0.8 (-1.3 to -0.4) |
| 18 Months | -1 (-1.4 to -0.5) | -0.8 (-1.3 to -0.4) |
| 24 Months | -1 (-1.4 to -0.5) | -0.6 (-1 to -0.1) |
| 36 Months | -0.7 (-1.2 to -0.2) | -0.7 (-1.2 to -0.2) |
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -1 (-1.7 to -0.3) | -1.4 (-2.1 to -0.6) |
| 12 Months | -0.9 (-1.6 to -0.2) | -1.1 (-1.8 to -0.4) |
| 18 Months | -0.9 (-1.6 to -0.2) | -1.2 (-1.9 to -0.5) |
| 24 Months | -1 (-1.7 to -0.3) | -0.9 (-1.7 to -0.1) |
| 36 Months | -1.2 (-2 to -0.5) | -0.9 (-1.7 to -0.1) |
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -0.8 (-1.3 to -0.3) | -0.9 (-1.4 to -0.4) |
| 12 Months | -1 (-1.5 to -0.5) | -0.7 (-1.3 to -0.2) |
| 18 Months | -0.9 (-1.5 to -0.4) | -0.9 (-1.5 to -0.4) |
| 24 Months | -1 (-1.6 to -0.5) | -0.6 (-1.2 to 0) |
| 36 Months | -0.8 (-1.4 to -0.3) | -0.5 (-1.1 to 0) |
The Body Image Scale measuring how the subjects feel about their appearance and about any changes that may have resulted from their condition consists of 8 questions. The questions are scored from 0=Not at all,..., 3=Very much. The score is calculated by summing the responses and ranges from 0 to 24. Higher scores correspond to worse body image. Change = Month \[6, 12, 18, 24, and 36\] Score - Baseline Score.
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | -5 (-6.1 to -3.8) | -3.7 (-4.9 to -2.6) |
| 12 Months | -4.9 (-6.1 to -3.7) | -3.9 (-5.1 to -2.7) |
| 18 Months | -4.8 (-6 to -3.6) | -3.9 (-5.1 to -2.7) |
| 24 Months | -4.8 (-6 to -3.6) | -3.8 (-5 to -2.6) |
| 36 Months | -4.9 (-6.1 to -3.7) | -3.8 (-5 to -2.6) |
The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.
| units on a scale | UPHOLD | USLS |
|---|---|---|
| 6 Months | 0.2 (0.1 to 0.4) | 0.3 (0.1 to 0.5) |
| 12 Months | 0.2 (0 to 0.4) | 0.3 (0.1 to 0.5) |
| 18 Months | 0.3 (0.1 to 0.4) | 0.2 (0.1 to 0.4) |
| 24 Months | 0.3 (0.1 to 0.5) | 0.3 (0.2 to 0.5) |
| 36 Months | 0.3 (0.1 to 0.5) | 0.3 (0.1 to 0.5) |
The Pelvic Organ Prolapse Quantification (POPQ) Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.
| cm | UPHOLD | USLS |
|---|---|---|
| 12 Months | -1.3 (-1.6 to -1) | -0.8 (-1.1 to -0.5) |
| 24 Months | -1.5 (-1.8 to -1.2) | -1.1 (-1.4 to -0.7) |
| 36 Months | -1.2 (-1.5 to -0.8) | -0.7 (-1 to -0.3) |
The Pelvic Organ Prolapse Quantification (POPQ) Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).
| cm | UPHOLD | USLS |
|---|---|---|
| 12 Months | -1.9 (-2.2 to -1.6) | -2 (-2.2 to -1.7) |
| 24 Months | -1.8 (-2.1 to -1.5) | -2 (-2.2 to -1.8) |
| 36 Months | -1.7 (-2.1 to -1.4) | -1.8 (-2.1 to -1.5) |
The Pelvic Organ Prolapse Quantification (POPQ) Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.
| cm | UPHOLD | USLS |
|---|---|---|
| 12 Months | -5.6 (-6.2 to -5) | -6.1 (-6.6 to -5.6) |
| 24 Months | -6 (-6.4 to -5.5) | -6.1 (-6.4 to -5.7) |
| 36 Months | -5.7 (-6.2 to -5.1) | -5.8 (-6.2 to -5.3) |
The Pelvic Organ Prolapse Quantification (POPQ) Total Vaginal Length (TVL) is the length of the vagina from posterior fornix tothe hymen when Point C or D is reduced to its full normal position.
| cm | UPHOLD | USLS |
|---|---|---|
| 12 Months | 8.5 (8.3 to 8.7) | 8 (7.7 to 8.2) |
| 24 Months | 8.6 (8.4 to 8.9) | 7.8 (7.5 to 8) |
| 36 Months | 8.5 (8.2 to 8.7) | 7.7 (7.4 to 8) |
The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).
| Participants | UPHOLD | USLS |
|---|---|---|
| 6 Months — No improvement | 79 | 81 |
| 6 Months — Improved | 8 | 4 |
| 12 Months — No improvement | 75 | 76 |
| 12 Months — Improved | 11 | 8 |
| 18 Months — No improvement | 70 | 76 |
| 18 Months — Improved | 12 | 7 |
| 24 Months — No improvement | 69 | 71 |
| 24 Months — Improved | 10 | 8 |
| 36 Months — No improvement | 70 | 67 |
| 36 Months — Improved | 8 | 8 |
Collected over 36 Months. Non-serious events are listed at a 0.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hysterectomy | 2/90 (2.2%) | 10/90 (11.1%) | 73/90 (81.1%) |
| Hysteropexy | 1/93 (1.1%) | 10/93 (10.8%) | 73/93 (78.5%) |
| Event | Hysterectomy | Hysteropexy |
|---|---|---|
| ColitisGastrointestinal disorders | 2/90 | 0/93 |
| Stress urinary incontinenceRenal and urinary disorders | 2/90 | 0/93 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/90 | 2/93 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/90 | 2/93 |
| Deep vein thrombosisVascular disorders | 0/90 | 2/93 |
| Colitis ischaemicGastrointestinal disorders | 1/90 | 0/93 |
| ConstipationGastrointestinal disorders | 1/90 | 0/93 |
| Diverticular perforationGastrointestinal disorders | 1/90 | 0/93 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/90 | 0/93 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/90 | 0/93 |
| Event | Hysterectomy | Hysteropexy |
|---|---|---|
| Urinary tract infectionInfections and infestations | 39/90 | 34/93 |
| Stress urinary incontinenceRenal and urinary disorders | 11/90 | 19/93 |
| Urge incontinenceRenal and urinary disorders | 13/90 | 19/93 |
| Suture exposure after 12 wks.Injury, poisoning and procedural complications | 17/90 | 3/93 |
| ConstipationGastrointestinal disorders | 13/90 | 5/93 |
| Excessive granulation tissue after 12 wks.Skin and subcutaneous tissue disorders | 10/90 | 1/93 |
| Faecal incontinenceGastrointestinal disorders | 4/90 | 10/93 |
| Ureteric kinkInjury, poisoning and procedural complications | 7/90 | 0/93 |
| Urinary retentionRenal and urinary disorders | 7/90 | 6/93 |
| Pelvic painReproductive system and breast disorders | 7/90 | 3/93 |
The baseline analysis population comprises all randomized participants that received the assigned intervention and were determined to still be eligible for the intervention after review of the initial POP-Q and PFDI-20.
| Age, Continuous(years) | UPHOLD | USLS | Total |
|---|---|---|---|
| Mean | 65.5 ± 7 | 66.2 ± 7 | 65.9 ± 7 |
| Sex/Gender, Customized(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| Female | 88 | 87 | 175 |
| Race/Ethnicity, Customized(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| American Indian/Alaskan Native | 0 | 4 | 4 |
| Asian | 2 | 1 | 3 |
| Black/African American | 8 | 3 | 11 |
| More than one race | 0 | 1 | 1 |
| Other | 5 | 1 | 6 |
| White | 73 | 77 | 150 |
| Race/Ethnicity, Customized(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| Hispanic/Latina | 9 | 7 | 16 |
| Not Hispanic/Not Latina | 76 | 78 | 154 |
| Unknown/Not Reported | 3 | 2 | 5 |
| Marital Status(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| Divorced, separated | 16 | 13 | 29 |
| Married/Living with partner | 56 | 58 | 114 |
| Single | 9 | 7 | 16 |
| Widowed | 7 | 9 | 16 |
| Education(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| 4-year College Degree | 16 | 20 | 36 |
| Associate College Degree | 22 | 19 | 41 |
| Graduate Degree | 11 | 15 | 26 |
| High School/GED | 31 | 26 | 57 |
| Less than High School | 6 | 5 | 11 |
| Unknown/Not Reported | 2 | 2 | 4 |
| Body Mass Index(kg/m^2) | UPHOLD | USLS | Total |
|---|---|---|---|
| Mean | 28.9 ± 4.0 | 28.2 ± 4.4 | 28.5 ± 4.2 |
| Current Smoker(Participants) | UPHOLD | USLS | Total |
|---|---|---|---|
| No | 85 | 86 | 171 |
| Yes | 3 | 1 | 4 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2013 to primary completion in Jul 2023, 123 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NICHD Pelvic Floor Disorders Network